Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTM1EQF)

DTT Name Oxysterols receptor LXR (NR1H)
Gene Name NR1H
DTT Type
Clinical trial target
 [1]
BioChemical Class
Nuclear hormone receptor
UniProt ID
NOUNIPROTAC
TTD ID
T71167

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
8 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ALX-101 DMCAFXM Atopic dermatitis EA80 Phase 2 [2]
RGX-104 DM5AIKR Non-small-cell lung cancer 2C25.Y Phase 1/2 [3]
BMS-779788 DMKR8S1 Arteriosclerosis BD40 Phase 1 [1]
BMS-852927 DMZS1D2 Arteriosclerosis BD40 Phase 1 [1]
CS-8080 DMRH740 Arteriosclerosis BD40 Phase 1 [1]
LXR 623 DM3OP41 Arteriosclerosis BD40 Phase 1 [1]
XL-041 DMYSQHT Arteriosclerosis BD40 Phase 1 [4]
XL652/XL014 DM89NML Cardiovascular disease BA00-BE2Z Phase 1 [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Clinical Trial Drug(s)
1 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
T0901317 DMZQVDI Discovery agent N.A. Investigative [6]
------------------------------------------------------------------------------------

References

1 Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Emerging small molecule drugs. Handb Exp Pharmacol. 2015;224:617-30.
5 Clinical pipeline report, company report or official report of Exelixis (2011).
6 The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res. 2003 Nov;44(11):2039-48.